Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

278 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT.
Robin M, Iacobelli S, Koster L, Passweg J, Avenoso D, Wilson KMO, Salmenniemi U, Dreger P, von dem Borne P, Snowden JA, Robinson S, Finazzi MC, Schroeder T, Collin M, Eder M, Forcade E, Loschi M, Bramanti S, Pérez-Simón JA, Czerw T, Polverelli N, Drozd-Sokolowska J, Raj K, Hernández-Boluda JC, McLornan DP. Robin M, et al. Among authors: perez simon ja. Bone Marrow Transplant. 2024 Mar 15. doi: 10.1038/s41409-024-02269-4. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 38491198
Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation.
Martino R, Caballero MD, Canals C, San Miguel J, Sierra J, Rovira M, Solano C, Bargay J, Pérez-Simon J, León A, Sarrá J, Brunet S, de la Cámara R; alloPBSCT and Infectious/nonifectious Complications Subcommittees of the Grupo Español de Transplante Hematopoyético (GETH). Martino R, et al. Bone Marrow Transplant. 2001 Aug;28(4):341-7. doi: 10.1038/sj.bmt.1703150. Bone Marrow Transplant. 2001. PMID: 11571505
Elderly age and prior autologous transplantation have a deleterious effect on survival following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results from the Spanish multicenter prospective trial.
Gómez-Núñez M, Martino R, Caballero MD, Pérez-Simón JA, Canals C, Mateos MV, Sarrá J, León A, Solano C, Moraleda JM, Urbano-Ispizua A, Besalduch J, Miguel JS, Sierra J. Gómez-Núñez M, et al. Bone Marrow Transplant. 2004 Mar;33(5):477-82. doi: 10.1038/sj.bmt.1704379. Bone Marrow Transplant. 2004. PMID: 14730333 Clinical Trial.
Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma.
van de Donk NW, Kröger N, Hegenbart U, Corradini P, San Miguel JF, Goldschmidt H, Perez-Simon JA, Zijlmans M, Raymakers RA, Montefusco V, Ayuk FA, van Oers MH, Nagler A, Verdonck LF, Lokhorst HM. van de Donk NW, et al. Bone Marrow Transplant. 2006 Jun;37(12):1135-41. doi: 10.1038/sj.bmt.1705393. Bone Marrow Transplant. 2006. PMID: 16757975
Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus.
Labrador J, López-Corral L, López-Godino O, Vázquez L, Cabrero-Calvo M, Pérez-López R, Díez-Campelo M, Sánchez-Guijo F, Pérez-López E, Guerrero C, Alberca I, Del Cañizo MC, Pérez-Simón JA, González-Porras JR, Caballero D. Labrador J, et al. Bone Marrow Transplant. 2014 May;49(5):684-90. doi: 10.1038/bmt.2014.17. Epub 2014 Feb 24. Bone Marrow Transplant. 2014. PMID: 24566710 Free article.
GVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT.
Parody R, Lopez-Corral L, Godino OL, Cadenas IG, Martinez AP, Vazquez L, Martino R, Martinez C, Solano C, Barba P, Valcarcel D, Caballero-Velazquez T, Marquez-Malaver FJ, Sierra J, Caballero D, Perez-Simón JA. Parody R, et al. Bone Marrow Transplant. 2015 Jan;50(1):121-6. doi: 10.1038/bmt.2014.220. Epub 2014 Oct 13. Bone Marrow Transplant. 2015. PMID: 25310306 Clinical Trial.
278 results